Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S40-S46 , 20 December 2007

Targeting acute hyperglycaemia in clinical practice

  • Simon Heller

      Affiliations

    • Corresponding Author InformationTel.: +44 114 271 2162; fax: +44 114 271 1863.

References 

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:683–689
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853
  3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes, UKPDS 38. BMJ. 1998;317:703–713
  5. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21–31
  6. Wolfe RR. Effects of insulin on muscle tissue. Curr. Opin. Clin. Nutr. Metab. Care. 2000;3:67–71
  7. Rodin J, Wack J, Ferrannini E, DeFronzo RA. Effect of insulin and glucose on feeding behavior. Metabolism. 1985;34:826–831
  8. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1992;327:1426–1433
  9. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;
  10. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes. 2005;54:757–764
  11. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354:617–621
  12. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macro-vascular complications in people with type 2 diabetes. Curr. Med. Res. Opin. 2005;21:989–998
  13. Leiter LA. From hyperglycemia to the risk of cardiovascular disease. Rev. Cardiovasc. Med. 2006;7(Suppl. 2):S3–S9
  14. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–885
  15. Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358:1709–1716
  16. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63:1373–1405
  17. Ota T, Takamura T, Kaneko S. Pioglitazone in nonalcoholic steatohepatitis. N. Engl. J. Med. 2007;356:1068;author reply 1068-9
  18. Schwartz AV. Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res. 2006;2006:1–6
  19. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427–2443
  20. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  21. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet. Med. 2007;24:223–232
  22. Barnett AH. Exenatide. Drugs Today (Barc). 2005;41:563–578
  23. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin. Invest. Drugs. 2007;16:231–237
  24. Wiedeman PE. DPPIV inhibition: promising therapy for the treatment of type 2 diabetes. Prog. Med. Chem. 2007;45:63–109
  25. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with Type 2 diabetes mellitus: a randomised controlled trial. Ann. Intern. Med. 1999;130:389–396
  26. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch. Intern. Med. 2005;165:1337–1344
  27. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;
  28. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  29. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711–1721
  30. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care. 2003;26:3273–3279
  31. ADVANCE Collaborative Group. ADVANCE—action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 2005;22:882–888
  32. Vasudevan AR, Burns A, Fonseca VA. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat. Endocrinol. 2006;5:273–286

PII: S0168-8227(07)00519-0

doi: 10.1016/j.diabres.2007.10.008

Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S40-S46 , 20 December 2007

Article Tools